Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Cantor Fitzgerald
Express Scripts

Generated: November 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,589,955

« Back to Dashboard

Summary for Patent: 6,589,955

Title: Pediatric formulation of gatifloxacin
Abstract:There is provided in accordance with the present invention the quinolone antibacterial gatifloxacin adequately taste-masked so that it can be utilized for pediatric formulations. A crystalline co-precipitate of gatifloxacin and one or both of stearic acid and palmitic acid in a narrow weight ratio has been found to effectively mask the bitter taste of gatifloxacin. The taste of gatifloxacin is effectively masked in the mouth and in aqueous suspension through a full dosage cycle, typically fourteen days. Gatifloxacin in the subject crystalline co-precipitates has been found to be readily available for absorption from the stomach.
Inventor(s): Raghavan; Krishnaswamy S. (Cranbury, NJ), Ranadive; Sunanda A. (East Brunswick, NJ), Bembenek; Kenneth S. (Dayton, NJ), Benkerrour; Loutfy (Paris, FR), Trognon; Veronique (La Turballe, FR), Corrao; Richard G. (Jackson, NJ), Esposito; Luigi (Howell, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:10/143,487
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Use; Process;

No matches for this query

International Patent Family for Patent: 6,589,955

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China1264514► Subscribe
Czech Republic20033487► Subscribe
Estonia200400018► Subscribe
European Patent Office1406572► Subscribe
Georgia, Republic ofP20053610► Subscribe
CroatiaP20031027► Subscribe
Hungary0401497► Subscribe
Israel158863► Subscribe
Iceland7048► Subscribe
Japan2005500306► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Federal Trade Commission
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus